COMPARISON OF DOSE REQUIREMENT, SERUM ERYTHROPOIETIN AND BLOOD-PRESSURE FOLLOWING INTRAVENOUS AND SUBCUTANEOUS ERYTHROPOIETIN TREATMENT OF DIALYSIS PATIENTS - IV AND SC ERYTHROPOIETIN
Jd. Jensen et al., COMPARISON OF DOSE REQUIREMENT, SERUM ERYTHROPOIETIN AND BLOOD-PRESSURE FOLLOWING INTRAVENOUS AND SUBCUTANEOUS ERYTHROPOIETIN TREATMENT OF DIALYSIS PATIENTS - IV AND SC ERYTHROPOIETIN, European Journal of Clinical Pharmacology, 50(3), 1996, pp. 171-177
Objective: The purpose of the study was to investigate the effect of r
oute of administration of erythropoietin (EPO) on the dose requirement
in dialysis patients after intravenous (IV) and subcutaneous (SC) the
rapy. Methods: The study was performed as a single centre, prospective
, open, combined parallel and cross-over study of 50 dialysis patients
, consecutively randomised to IV., SC treatment with EPO. The initial
dose was 40 U . kg(-1) 3-times weekly, adjusted to increase haemoglobi
n (Hgb) from a median 5.3 mmol . l(-1) to a target of haemoglobin 6.5-
7.5 mmol . l(-1). After reaching the target level, the haemoglobin was
maintained for 4 months (Period I). Then IV and SC treatment was swit
ched for a further 4 months (Period 2). The study included high risk p
atients. The adjustment period was completed by 38 patients, Period on
e by 32 patients (IV/SC = 15/17; male/female = 19/13; age = 54 (24-71)
y), and Period two by 22 patients. Results: No significant difference
was found between the two groups in the reticulocyte response, the ra
te of Hgb increase (IV 0.7 versus SC 0.5, mmol . l(-1) . month(-1)), t
ime to reach target level (IV 43 versus SC 60 days), or total EPO dose
per increase in haemoglobin to target level (TV 663 versus SC 946 (U
. kg(-1)) per (mmol Hgb . l(-1)). The overall median maintenance dose
during the last month of the two four month periods was 105 (range IV
51-336) U . kg(-1) . w(-1) and SC 104 (range 21-321) U . kg(-1) . w(-1
). Trough serum EPO levels were significantly higher during SC treatme
nt. The blood pressure did not change significantly from the base leve
l after either route of administration; start 133/80 versus 143/80 mmH
g, target 127/78 versus 154/85 mmHg, and maintenance period 140/84 ver
sus 142/85 mmHg. Thus, three-times weekly IV or SC EPO did not differ
significantly in efficacy or in the effect on blood pressure in dialys
is patients.